$74.08
1.69% today
Nasdaq, Sep 30, 06:45 pm CET
ISIN
US6047491013
Symbol
MIRM

Mirum Pharmaceuticals Inc Stock price

$72.85
-1.02 1.38% 1M
+27.80 61.71% 6M
+31.50 76.18% YTD
+33.85 86.79% 1Y
+51.86 247.07% 3Y
+53.49 276.29% 5Y
+59.64 451.48% 10Y
+59.64 451.48% 20Y
Nasdaq, Closing price Mon, Sep 29 2025
+0.09 0.12%
ISIN
US6047491013
Symbol
MIRM
Industry

Key metrics

Basic
Market capitalization
$3.7b
Enterprise Value
$3.7b
Net debt
$4.4m
Cash
$304.6m
Shares outstanding
50.1m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
8.5 | 7.1
EV/Sales
8.5 | 7.1
EV/FCF
negative
P/B
14.3
Financial Health
Equity Ratio
33.6%
Return on Equity
-39.0%
ROCE
-9.8%
ROIC
-
Debt/Equity
1.2
Financials (TTM | estimate)
Revenue
$429.2m | $515.7m
EBITDA
$-32.9m | $-18.2m
EBIT
$-57.1m | $-35.0m
Net Income
$-58.6m | $-36.3m
Free Cash Flow
$-1.4m
Growth (TTM | estimate)
Revenue
62.3% | 53.1%
EBITDA
63.0% | 71.5%
EBIT
47.4% | 60.1%
Net Income
46.4% | 58.8%
Free Cash Flow
96.5%
Margin (TTM | estimate)
Gross
79.0%
EBITDA
-7.7% | -3.5%
EBIT
-13.3%
Net
-13.7% | -7.0%
Free Cash Flow
-0.3%
More
EPS
$-1.2
FCF per Share
$0.0
Short interest
14.9%
Employees
322
Rev per Employee
$1.1m
Show more

Is Mirum Pharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,009 stocks worldwide.

Mirum Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

17 Analysts have issued a Mirum Pharmaceuticals Inc forecast:

16x Buy
94%
1x Hold
6%

Analyst Opinions

17 Analysts have issued a Mirum Pharmaceuticals Inc forecast:

Buy
94%
Hold
6%

Financial data from Mirum Pharmaceuticals Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
429 429
62% 62%
100%
- Direct Costs 90 90
23% 23%
21%
339 339
77% 77%
79%
- Selling and Administrative Expenses 228 228
29% 29%
53%
- Research and Development Expense 168 168
38% 38%
39%
-33 -33
63% 63%
-8%
- Depreciation and Amortization 24 24
23% 23%
6%
EBIT (Operating Income) EBIT -57 -57
47% 47%
-13%
Net Profit -59 -59
46% 46%
-14%

In millions USD.

Don't miss a Thing! We will send you all news about Mirum Pharmaceuticals Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Mirum Pharmaceuticals Inc Stock News

Neutral
Business Wire
20 days ago
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
Neutral
Seeking Alpha
22 days ago
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM ) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 8:30 AM EDT Company Participants Christopher Peetz - CEO & Director Conference Call Participants Michael Ulz - Morgan Stanley, Research Division Presentation Michael Ulz Equity Analyst All right. Good morning, everyone, and thanks for joining us at the Morgan Stanley Global Healt...
Neutral
Business Wire
22 days ago
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced the completion of enrollment in the Phase 2b VISTAS study of volixibat, an investigational oral IBAT inhibitor, for the treatment of cholestatic pruritus in patients with primary sclerosing cholangitis (PSC). The trial previously met its pre-specified efficacy and safety thresholds at the blinded in...
More Mirum Pharmaceuticals Inc News

Company Profile

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The firm focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Its product candidates include Maralixibat and Volixibat. The company was founded by Niall O'Donnel, Michael Grey and Christopher Peetz on May 7, 2018 and is headquartered in Foster City, CA.

Head office United States
CEO Christopher Peetz
Employees 322
Founded 2018
Website mirumpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today